AVA-101

N/A

Report date: 2023/12/11 18:14:32

Base Information

Drug NameAVA-101
Drug Alias NameAVA-101
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityB-lymphocyte antigen CD19 inhibitors +[4] 
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsLymphoma, Non-HodgkinPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAvalon Globocare Corp
China Registration ClassN/A

Develop Information

Active CompaniesAvalon Globocare Corp
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-HodgkinPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A